Quick Answer
Theriva Biologics, Inc. reported Stockholders Equity of $15.38 million for fiscal year 2025.
Theriva Biologics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $15.38M | -19.3% |
| 2024 | $19.07M | -48.4% |
| 2023 | $36.96M | -28.7% |
| 2022 | $51.83M | -8.1% |
| 2022 | $56.39M | -9.4% |
| 2022 | $62.22M | -8.5% |
| 2022 | $68.03M | +4.0% |
| 2021 | $65.41M | +1472.1% |
| 2020 | -$4.77M | -361.8% |
| 2019 | $1.82M | -63.1% |
| 2019 | $4.93M | -71.1% |
| 2018 | $17.07M | +1240.9% |
| 2017 | -$1.50M | -138.9% |
| 2016 | $3.85M | -76.0% |
| 2015 | $16.05M | +68.0% |
| 2014 | $9.56M | -37.3% |
| 2013 | $15.23M | +16.9% |
| 2012 | $13.03M | +84.6% |
| 2011 | $7.06M | +97.2% |
| 2010 | $3.58M | +1.0% |
| 2009 | $3.54M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.74M | -72.6% | -36.6% |
| June 30, 2025 | $10.62M | -59.0% | -31.5% |
| March 31, 2025 | $15.50M | -50.6% | -18.7% |
| December 31, 2024 | $19.07M | -48.4% | -22.6% |
| September 30, 2024 | $24.64M | -40.1% | -4.9% |
| June 30, 2024 | $25.90M | -42.5% | -17.5% |
| March 31, 2024 | $31.39M | -34.4% | -15.1% |
| December 31, 2023 | $36.96M | -28.7% | -10.2% |
- Theriva Biologics, Inc. showed a decrease of -19.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2009–2025 period, Theriva Biologics, Inc.’s stockholders equity has grown by 333.9% (from $3.54 million to $15.38 million).
- The most recent figure is from Theriva Biologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: